YM155 (Sepantronium Bromide)

Catalog No.S1130

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

12 Customer Reviews

  • Dose response of ALL cell lines to YM155. Asynchronous populations of cells were treated with increasing doses of YM155 for 72 h. Then, viability was measured by MTS and normalized to no drug control. S.e.m. bars are inserted. Dotted line represents 50% viability.

    Leukemia 2012 26, 623-632. YM155 (Sepantronium Bromide) purchased from Selleck.

    Treatment of SUPB15 cells with imatinib or YM155. Top panel shows cells treated with siRNA in the presence of 500 nM imatinib. Cells were treated with siRNA, and then subsequently incubated in 500 nM imatinib for 96 h. Bottom panel shows the partial rescue of SUPB15 cells treated with 100 nM YM155 for 96 h. S.e.m. bars are inserted into each graph.

    Leukemia 2012 26, 623-632. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Inhibition of survivin expression restricts VZV repl ication and sprea d in vitro . ( A ) HEL F were infected w ith VZV-GFP in the presence of YM155 or DMSO, and infectious virus yields were determined at 48 hpi by titration on melanoma cells. ( B) VZV-GFP-infected HELF were treated with DMSO or YM155; plaques were detected by staining with anti-VZV IgG at 48 hpi. Plaque sizes were determined using ImageJ; the graph shows the mean size ?S EM o f 30 plaques . (C )Expression of VZV proteins was assessed in VZV-infected HELF lysat e s (24 hp i) treated with YM155 or DMSO.

    Proc Natl Acad Sci U S A 2012 109, 600-5. YM155 (Sepantronium Bromide) purchased from Selleck.

    MM cell lines UM9 (left panel) or U266 (right panel) were cultured in presence or absence of accessory cells prior to incubation with CTLs alone, YM155 alone or the combination. Survival of UM9 and U266 MM cells was assessed by CS-BLI. Results show % lysis of MM cells after 24 hour incubation and are depicted for three doses.

    Clin Cancer Res 2013 19, 5591-601. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Survivin inhibitor increased apoptosis in burn serum-stimulated cardiomyocytes. a YM155 increased apoptosis in burn serumstimulated cardiomyocytes in a concentration-dependent manner. Neonatal rat cardiomyocytes were treated with YM155 (3-300 nM at the indicated) for 2 h prior to stimulation burn serum for 12 h. The extent of DNA fragmentation was quantified using the Cell Death Detection ELISA. versus 0 nM YM155 plus stimulation with burn serum. b YM155 (100 nM) pretreatment increased the apoptosis production at 2 or 12 h after burn serum stimulation. c Representative blots of survivin and cleaved caspase-3 in YM155 (100 nM) pretreated cardiomyocytes at 2 and 12 h after burn serum stimulation. d Bar graphs show the relative proteins.

    Basic Res Cardiol 2011 106, 1207-1220. YM155 (Sepantronium Bromide) purchased from Selleck.

    Induction of cardiomyocytes apoptosis by survivin inhibitor in vivo. After YM155 was administered (5 mg/kg/day) for 5 days, the rats were exposed to a 40% TBSA burn (burn injury) or 25C water (sham) and killed 6 h after burn injury. The frozen sections of the ventricular tissues or whole cell lysates were prepared. Apoptotic staining was performed using the TUNEL method and immunostained using a-sarcomeric actin. The survivin and cleaved caspase-3 levels were measured by Western blot analysis. a Representative blots of survivin and cleaved caspase-3. b The statistical analysis of the relative proteins .c Figures are representative of two independent TUNEL experiments. Green fluorescence represents apoptotic cells, whereas red stain indicates staining for a-sarcomeric actin specific for cardiac myocytes. d Bar graph summarizes the counted apoptotic cells.

     

     

    Basic Res Cardiol 2011 106, 1207-1220. YM155 (Sepantronium Bromide) purchased from Selleck.

  • YM-155 sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 and B. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for up to 6 h. Then apoptotic cells were assessed as in Figure 2A and2B (representative apoptotic cells were marked with white arrows). C. LH86 and D. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for 6 h. Cells with apoptotic nuclei were counted to determine cell death ratio (*p<0.05, **p<0.05). E. LH86 cells and F. Huh7 cells were treated as indicated and cell lysates were prepared and subjected to Western blotting.Apoptosis was evaluated through caspase 3 activation. b-actin was used as an equal protein loading control. G. LH86 cells grown in six-well plate were untreated (control) or treated with different conditions as indicated for 48 h. After rinsed with fresh culture medium for 3 times, cells were cultured for another two weeks. Cell colony formation assays were performed with crystal violet staining. H. colony number were counted to show combination treatment with ABT-263 and YM-155 resulted in reduction of clonogenesis (#p<0.05).

    PLoS One 2011 6, e21980. YM155 (Sepantronium Bromide) purchased from Selleck.

    Survivin down-regulation sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 cells were treated as indicated and cell lysates were prepared for Western blotting. Pro-apoptotic proteins: Bax, Bad, and Bak and anti-apoptotic proteins Bcl-xL and Mcl-1 were assessed with specific antibodies respectively. b-actin was detected and served as an equal protein loading control. B. LH86 cells were untreated or treated with ABT-263 (1 μM), YM-155 (1 μM) or combination of ABT-263 (1 μM) and YM155 (1 μM) for up to 6 h as indicated. Then cells were harvested and cell lysates were prepared for Western blotting. Anti-survivin and anti-Bcl-xL polyclonal antibodies were used to assess protein levels for survivin and Bcl-xL respectively. b-actin was used as an equal protein loading control. The band intensities of survivin, Bcl-xL, and b-actin was qualified with Image J software. C. LH86 cells were transiently transfected with synthesized random siRNA (control) or survivin specific siRNA duplexes, and 48 h posttransfection, cells were subjected to Western blotting analysis with anti-survivin polyclonal antibody. β-actin was used as an equal protein loading control. D. LH86 cells were transfected with synthesized random control siRNA or survivin specific siRNA, and 48 h post-transfection, cells were untreated or treated with ABT-263 (1 μM) for 24 h and then subjected to Hoechst staining to show apoptotic cells with condensed nuclei (representative apoptotic cells were marked with white arrows). E. LH86 cells were treated as in Figure 4D and apoptosis was measured as in Figure 2A. Statistical analysis was performed for apoptosis ratio by counting the number of cells with apoptotic nuclei (*p<0.05). F. LH86 cells treated as in Figure 4D were harvested and cell lysates were prepared and subjected to Western blotting. Apoptosis was determined through caspase 3 activation. β-actin was used as an equal protein loading control.

    PLoS One 2011 6, e21980. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Effects of YM155 on cell viability (A) and cell cycle (B), and on experiment of survivin mRNA (C) and protein (D) in the MiaPaCa-2 human pancreatic cancer cell line.

    Anticancer Res 2012 32, 1681-8. YM155 (Sepantronium Bromide) purchased from Selleck.

     

    IPF fibroblasts from 8 different patients were cultured to 60% confluence in DMEM supplemented with 10% fetal bovine serum and growth-arrested for 24 hours in serum-free DMEM prior to treatment for 16 hours with/without the Fas-activating antibody CH11 (FasL; 250 ng/ml) in the presence/absence of the survivin inhibitors CAY10625 (5 µM) or YM155 (10.0 µM), or with the survivin inhibitors alone. (a) Apoptosis was assessed using ELISA-based detection of histone associated DNA fragments. To allow relative comparisons of apoptosis across experiments, the data for each cell line is expressed as the percentage of the assay positive control that was included on each ELISA plate. The scatter plot shows the distribution of responses in individual cell lines along with the mean ± standard error for each treatment group. p = 0.038 overall (ANOVA). p = 0.027 for FasL compared to FasL/CAY10625, and p = 0.046 for FasL compared to FasL/YM155; (b) The correlation of apoptosis between IPF fibroblasts treated with FasL/CAY10625 and FasL/YM155. Each point represents a different IPF cell line. The Spearman correlation (r) = 0.95.
     

    Adv Biosci Biotechnol 2012 3, 657-664. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Total RNA from livers of these mice were isolated from tissues using TRIZOL (Invitrogen). cDNA synthesis was performed with the M-MLV RTase cDNA Synthesis Kit (Promega). qRT-PCR reactions were performed using SYBR Green (Takara) on ABI 7500 Fast system. Expression levels of Survivin gene were measured by qRT-PCR in livers injected with 0.9% Nacl (91#,92#) or YM155 48 hours after DEN treatment.

    Lihua Min of Chinese Academy of Sciences. YM155 (Sepantronium Bromide) purchased from Selleck.

    Western blot analysis of Survivin. U-251 and PC-3 cell line was treated with 0-100nM YM-155.

     

     

    Dr. Chunrong Yu of RoswelI Park Cancer Institute. YM155 (Sepantronium Bromide) purchased from Selleck.

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 NXS4XGYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nRR|czKGh? NF;tNI5FVVOR NUjWNYZWUUN3ME2wMlAxQSEEsTCwMlAxODlizszN NGPDW2gzPTZ3OUezNS=>
M-07e NYrVNm5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfOO|IhcA>? NGHkVJBFVVOR MkPuTWM2OD1yLkC0NEDDuSByLkCxN{DPxE1? MV:yOVY2QTd|MR?=
THP-1 M3WwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;ZeFczKGh? MlO3SG1UVw>? MXrJR|UxRTBwMEWxJOKyKDBwMEGzJO69VQ>? MXuyOVY2QTd|MR?=
CMK NH3sO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[3NkBp M2rmXWROW09? MmfPTWM2OD1yLkC1N{DDuSByLkCwPUDPxE1? MmfFNlU3PTl5M{G=
MV4-11 NXTXW2gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLGc3M4OiCq Mn;0SG1UVw>? M2e3TmlEPTB;MD6wOVUhyrFiMD6wNlgh|ryP MYqyOVY2QTd|MR?=
AML-193 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO3NkBp M4nWb2ROW09? M3H0b2lEPTB;MD60OlIhyrFiMD6wOlAh|ryP NFXVPHMzPTZ3OUezNS=>
HL-60 M1LvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3yRo41PzJiaB?= NHjrW3FFVVOR MXvJR|UxRTBwMECxJOKyKDBwMECwNkDPxE1? MnS4NlU3PTl5M{G=
ML-2 M4Dx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTGXFY4OiCq MVTEUXNQ Mk\KTWM2OD1yLkCwPUDDuSByLkCwNkDPxE1? MnH1NlU3PTl5M{G=
OCI/AML3 NVnFVWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO3NkBp NUH0VGJXTE2VTx?= NXW2W5hsUUN3ME2wMlAyOSEEsTCwMlAxOiEQvF2= MWCyOVY2QTd|MR?=
HEL M37FT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7xT5dsPzJiaB?= MWHEUXNQ MlzOTWM2OD1yLkW1PUDDuSByLkCzPEDPxE1? MUeyOVY2QTd|MR?=
ME-1 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37XRVczKGh? NH[0dYtFVVOR M{jSfGlEPTB;MD62PFQhyrFiMD6xO|kh|ryP M37TcFI2PjV7N{Ox
THP-1 NEG3WVdCeG:ydH;zbZMhSXO|YYm= MWqxxsDPxE1? NYX3b|kyPzJiaB?= MULEUXNQ MkfSbY5lfWOnczDhdI9xfG:|aYO= MnjVNlU3PTl5M{G=
M-07e NF3WZ5ZHfW6ldHnvckBCe3OjeR?= MorNNQKBmzIEoN88US=> NVu4fZB4PzJiaB?= MkTCSG1UVw>? M2\NOYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= MlzpNlU3PTl5M{G=
THP-1 NHf6WnpHfW6ldHnvckBCe3OjeR?= NUjNUohNOOLCk{JCpO69VQ>? MmHjO|IhcA>? NIDrZlJFVVOR MknjbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= M163OFI2PjV7N{Ox
CMK MknrSpVv[3Srb36gRZN{[Xl? MXyw5qCUOcLizszN MXS3NkBp M1zjSmROW09? Mn;obY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= MkXkNlU3PTl5M{G=
AML-193 MV7GeY5kfGmxbjDBd5NigQ>? MoLTNQKBmzIEoN88US=> MYG3NkBp NF36N21FVVOR NV3RfYc3cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MYKyOVY2QTd|MR?=
Kasumi-1 MmnSSpVv[3Srb36gRZN{[Xl? MnrTNQKBmzIEoN88US=> NWjh[pVHPzJiaB?= NWe5UnllTE2VTx?= NYTEfWk2cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> NWi3dHNlOjV4NUm3N|E>
MV4-11 NV3rPVN2TnWwY4Tpc44hSXO|YYm= Mnv0NQKBmzIEoN88US=> NVjkb3dkPzJiaB?= Mm\tSG1UVw>? MVTpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NEm0TGszPTZ3OUezNS=>
MUG-Chor  MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMVUh|ryP M3jqWlI1NzR6IHi= NY\rcFlbUUN3ME23MlA26oDLbl2g[o9zKDR6aB?= NXn3Z2U4OjV4NECxPFU>
U-CH1  NUjadYx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nmclAuPSEQvF2= NFLEUnQzPC92ODDo MV\JR|UxRTlwMERihKlvVSCob4KgOFhp MWqyOVY1ODF6NR?=
KATOIII MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[xNE8zOCCwTR?= NEPmbGg1QCCq M{T6NYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWiyOVY{PTB3NR?=
AGS  M4jnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rCe|ExNzJyIH7N NIH6VnY1QCCq M4nRXolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{HUNVI2PjN3MEW1
SACC-83 M{HhUWZ2dmO2aX;uJGF{e2G7 M2LiZ|Uhdk1? NVHF[2F1PDhiaB?= M3v5fYRm[3KnYYPld{BvfWOuZXHyJIV5eHKnc4Ppc44hd2ZiSFnGMVHPuQ>? MY[yOVQ5PTZ|NR?=
INA-6 M3PF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rNXVAuPTByIH7N MVW0PEBp NVyze2RbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoDjNlUzQTZ7N{i=
U-266 NIHncJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HqUFAuPTByIH7N MXO0PEBp MnPUbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFG3VoUzPTJ7Nkm3PC=>
MOLP-8 NEP4PXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYewMVUxOCCwTR?= Ml;rOFghcA>? M3Xt[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NELxb2QzPTJ7Nkm3PC=>
HG-1 NIDWTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGwMVUxOCCwTR?= M1\tdlQ5KGh? M{f3TolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFS4TGczPTJ7Nkm3PC=>
NCI-H929 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LLR|AuPTByIH7N MmfZOFghcA>? MkHxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MV:yOVI6Pjl5OB?=
OPM-2 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P3OVAuPTByIH7N NVjJcJg{PDhiaB?= NVHFR|VZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWmyOVI6Pjl5OB?=
L-363 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO3fZExNTVyMDDuUS=> MUK0PEBp MV7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NU\VeYdKOjV{OU[5O|g>
MOLP-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnLUooxNTVyMDDuUS=> MoLrOFghcA>? M{jud4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmHKNlUzQTZ7N{i=
KMS-12-BM MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLsNE02ODBibl2= NGTS[3Y1QCCq M{\NeIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXHtRmNjOjV{OU[5O|g>
SK-MM-2 NFrUNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX4ZY4xNTVyMDDuUS=> NF\peFg1QCCq MVfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVL6PVlLOjV{OU[5O|g>
U-266 MXjBdI9xfG:|aYOgRZN{[Xl? NYW5b3ZvOC13MDDuUS=> M2TmO|I1KGh? MVjpcoR2[2W|IHHwc5B1d3Orcx?= MYGyOVI6Pjl5OB?=
INA-6  M4njN2Fxd3C2b4Ppd{BCe3OjeR?= M3;NWFAuPTBibl2= MYiyOEBp NWLD[ZpqcW6mdXPld{BieG:ydH;zbZM> Mn3wNlUzQTZ7N{i=
MCF7 NXm5bXBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnuO|IhcA>? NVj0V5RsUUN3ME2xN{DDuSB4IH7N MVyyOVIzODJ{NR?=
MCF7-TamR6 Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrZO|IhcA>? MlHhTWM2OD16INMxJFYhdk1? MkniNlUzOjB{MkW=
MCF7-TamR7 M3TV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK1O|IhcA>? NFHKZlZKSzVyPUigxtEhOyCwTR?= M1LxN|I2OjJyMkK1
MCF7-TamR8 NW[we4ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTP[5lnPzJiaB?= MVjJR|UxRTF3INMxJFYhdk1? NGDCVmwzPTJ{MEKyOS=>
MCF7-TamC3 NF7j[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2xTG04OiCq NGLIcJhKSzVyPU[gxtEhOyCwTR?= M1TZWVI2OjJyMkK1
MCF7-TamC6 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHDO|IhcA>? M1rQb2lEPTB;NjFCtUAxNjFibl2= MoPxNlUzOjB{MkW=
MDA-MB-231 NGrBR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYi3NkBp NXzYd3B[UUN3ME21JOKyKDFibl2= M2\XT|I2OjJyMkK1
SK-BR-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHEOIY{PzJiaB?= M4XON2lEPTB;NzFCtUAxNjNibl2= M3;6VlI2OjJyMkK1
Eca109 NYHVZms4TnWwY4Tpc44hSXO|YYm= MnSwNU02OCCwTR?= NFHYTIo1QCCq MoTDSG1UVw>? M{\sbpN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NVjJV4wxOjVzM{mzPVU>
TE13 MXzGeY5kfGmxbjDBd5NigQ>? MlrwNU02OCCwTR?= MlfsOFghcA>? MX\EUXNQ M4DyNZN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHfZ[XgzPTF|OUO5OS=>
Eca109 M2DQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLCNE0yODBibl2= MmPsNlQwPDhiaB?= MV;EUXNQ MYDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnjYNlUyOzl|OUW=
TE13 NFvtW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS0U5QxNTFyMDDuUS=> M1nXVFI1NzR6IHi= MnvZSG1UVw>? M2noXYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGewVGEzPTF|OUO5OS=>
MT-3 NHrjUWFMcW6jc3WgRZN{[Xl? NYPsdIFsPzJiaB?= MXTEUXNQ MkPsTWM2OD1{Lki2JOKyKDBwNUSgcm0h\m:{IFTSOEBmgHC{ZYPzbY9v NYnJPWxHOjR6Nk[1PFU>
MDA-MB-468 MUHLbY5ie2ViQYPzZZk> MlPnO|IhcA>? Mmr4SG1UVw>? MoHWTWM2OD1yLkGxJOKyKDBwMEGgcm0h\m:{IFTSOEBmgHC{ZYPzbY9v MoT0NlQ5PjZ3OEW=
SUM-159 MWHLbY5ie2ViQYPzZZk> NFn0e|E4OiCq MYLEUXNQ M4XVPGlEPTB;MT63NkDDuSByLkOzJI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? MXGyOFg3PjV6NR?=
MT-3 NY\YRmZ7U2mwYYPlJGF{e2G7 NHf6NJA4OiCq NUjMWXlSTE2VTx?= NIHuSYZKSzVyPUW0MlEyKMLzIESuN|Ihdk1iZn;yJGRTPSCneIDy[ZN{cW:w M3SzOVI1QDZ4NUi1
MDA-MB-468 Mkf0T4lv[XOnIFHzd4F6 NVHTfGR{PzJiaB?= NVG0[5g2TE2VTx?= MYPJR|UxRTBwMEegxtEhOC5yMjDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> MonpNlQ5PjZ3OEW=
SUM-159 NY\WZVN1U2mwYYPlJGF{e2G7 NHzpdow4OiCq MVTEUXNQ NEjIemtKSzVyPU[5MlQhyrFiND6yN{BvVSCob4KgSHI2KGW6cILld5Nqd25? MmXTNlQ5PjZ3OEW=
MT-3 + NAC M2XIS2tqdmG|ZTDBd5NigQ>? NF[1[Go4OiCq NEnPSJpFVVOR NV32U3JGUUN3ME21Ok4zKMLzIEKuNFchdk1iZn;yJGRTPSCneIDy[ZN{cW:w NUTDNGlNOjR6Nk[1PFU>
MT-3 + SB203580 MXLLbY5ie2ViQYPzZZk> NGrJNHQ4OiCq MmDFSG1UVw>? NXzaUo9oUUN3ME2zPE41OSEEsTC1MlAzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= MnjiNlQ5PjZ3OEW=
DB MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;pTYVVOTBibl2= NWH4OWFYOjRiaB?= MnnFSG1UVw>? NF;2U3BqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MVeyOFQ5PjV7NR?=
SU-DHL-8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGxNEBvVQ>? MmfYNlQhcA>? M{fsb2ROW09? NXL2[|c1cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v Mnf0NlQ1QDZ3OUW=
WSU-DLCL2 M1vmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\3fpJNOTBibl2= MkDxNlQhcA>? NX2yUWo1TE2VTx?= NY\z[nVJcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NIq4[2gzPDR6NkW5OS=>
ACC-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n5[|AuOTByIH7N NH7ZXWEzPCCq MljrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWmyOFM4ODl7NR?=
ACC-2 NWWzdYlYSXCxcITvd4l{KEG|c3H5 M{nEfFAuOjBibl2= M{fEZ|I1KGh? NYKxUopbcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVeyOFM4ODl7NR?=
ACC-2 M1HCTmZ2dmO2aX;uJGF{e2G7 NV7MbVlbOC1{MDDuUS=> NXPkTYo2OjRiaB?= NVq4XolocW6lcnXhd4V{KHSqZTDjc453\XK|aX;uJI9nKEyFM1mgeI8hVEN|SVm= NWDyPIpsOjR|N{C5PVU>
BFTC905 NGrFOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTXpVYOC1zMECwJI5O NFO5WYs1QCCqwrC= MUPEUXNQ MVTJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVqzdIVZOjR{OUe2OFQ>
T24 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rCZ|AuOTByMDDuUS=> MmLmOFghcMLi NWKySo5mTE2VTx?= MkLHTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NW\vWId[OjR{OUe2OFQ>
TSGH8301  MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILwNVQxNTFyMECgcm0> M3zL[FQ5KGkEoB?= MnfqSG1UVw>? NFe5T4dKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUDwNnYxOjR{OUe2OFQ>
BFTC909 NFHte|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPlNE0yODByIH7N M4fnO|Q5KGkEoB?= M2TzNGROW09? NWSxZnJlUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHvYS|AzPDJ7N{[0OC=>
BFTC905 NVTXfmliSXCxcITvd4l{KEG|c3H5 NUjIXVd2OjBibl2= M1vodlQ5KGh? MV7EUXNQ NELrc|lqdmS3Y3XzJIFxd3C2b4Ppdy=> MVKyOFI6PzZ2NB?=
BFTC905 NFn0VJBHfW6ldHnvckBCe3OjeR?= MkTVNlAhdk1? NEmwSpA1QCCq MmjySG1UVw>? NHrnfGll\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|Qj3JTS=> NFznUoMzPDJ7N{[0OC=>
A2780p NWPt[WdITnWwY4Tpc44hSXO|YYm= NEnuTZQxNTFyMDDuUS=> MkLZNlQhcA>? MlnLSG1UVw>? NUHPNmhZcW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg M2npTFI1OjZ{OEe1
A2780cis NXznS5VCTnWwY4Tpc44hSXO|YYm= M3LFclAuOTByIH7N MUSyOEBp M3XaXGROW09? MV\pcoR2[2W|IGP1dpZqfmmwIHTve45z\We3bHH0bY9vyqB? NVPkR3JXOjR{NkK4O|U>
A2780p MWXBdI9xfG:|aYOgRZN{[Xl? Mle5OU0yODBibl2= NHT2dYczPC92ODDo M1HGTGROW09? NHHrT5JqdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NYC5bFhyOjR{NkK4O|U>
A2780cis Mn;3RZBweHSxc3nzJGF{e2G7 MkKwOU0yODBibl2= MnzaNlQwPDhiaB?= Ml7tSG1UVw>? MVfpcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy M4HCcVI1OjZ{OEe1
SH-SY5Y MXTBdI9xfG:|aYOgRZN{[Xl? NE\zNI8yNzFyL{GwNEDDvU1? MlT3O|IhcA>? MWXEUXNQ Ml3tbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUGyOFI2PDV4MB?=
HL-60 M2\1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7vNVQ4OsLiaB?= NIfIVIFFVVOR Mmi1TWM2OD1yLkOgcm0> Mn3mNlM3OTh6NkK=
U937  NWj6cFJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGxO|LDqGh? MVnEUXNQ NX;PUJJNUUN3ME2wMlghdk1? NV;mPYg6OjN4MUi4OlI>
HL-60  M12wTmZ2dmO2aX;uJGF{e2G7 MYWxxsDPxE1? M4PrSlYwOTJxMkSgbC=> NEDoUINFVVOR NHXtVI1qdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> MnL2NlM3OTh6NkK=
U937  NHXOblFHfW6ldHnvckBCe3OjeR?= MWmxxsDPxE1? MVG2M|EzNzJ2IHi= MVHEUXNQ NFHGb5JqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> M1;4dlI{PjF6OE[y
HL-60 NW\YOFZQSXCxcITvd4l{KEG|c3H5 MkXKNE4yNzFizszN M4H0[lghcA>? NWixfHFjTE2VTx?= MXXpcoR2[2W|IHHwc5B1d3Orcx?= Mlm1NlM3OTh6NkK=
Sk-NEP-1  Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOxMVExODByIH7N M1jUUFI1KGh? M1vRRWROW09? NUH1d5ZRUUN3ME2xNFAhdk1? MV6yN|I3PzZ7OR?=
SK-NEP-1  M{nuTWFxd3C2b4Ppd{BCe3OjeR?= MoC1OVAwOTByIH7N NXHrb|d1OTJxMkSgbC=> NV64SldrTE2VTx?= NWXPcmx4cW6mdXPld{BieG:ydH;zbZM> M1vseVI{OjZ5Nkm5
TC-32 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMlEuOTByMDDuUS=> NEnvXFFGSzVyPUOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGW1cVAzOjl4MUe2Ny=>
TC-71 M3fsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiwN4kxNjFvMUCwNEBvVQ>? MXjFR|UxRTVwNzDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVewOXJ7OjJ7NkG3OlM>
SK-ES-1 NH[yT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zHO|AvOS1zMECwJI5O MYXFR|UxRTJwODDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWHYWJh5OjJ7NkG3OlM>
RD-ES Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfjNE4yNTFyMECgcm0> MW\FR|UxRTZwMjDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnLzNlI6PjF5NkO=
HEK293 NEXJbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjiS4FpOC5zLUGwNFAhdk1? NIO2cmRGSzVyPUKzMlAhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUCyNlk3OTd4Mx?=
M059J MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MViwMVUxKG6P M1Hzb|Q5KGh? Mli1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVqyNlc4ODFzMB?=
M059K MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP6[pgxNTVyIH7N M33KXFQ5KGh? MnTDbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4L2XVIzPzdyMUGw
M059J MXPBdI9xfG:|aYOgRZN{[Xl? M3\se|MxKG6P Mor6NlQhcA>? MXLpcoR2[2W|IHHwc5B1d3Orcx?= M1vncFIzPzdyMUGw
M059K MWDBdI9xfG:|aYOgRZN{[Xl? NXfNW5d7OzBibl2= NFrHXWUzPCCq M1LkZ4lv\HWlZYOgZZBweHSxc3nz MmXiNlI4PzBzMUC=
PANC-1 M1PucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PZbFAvODFvMUCwNEBvVQ>? NY\m[mxHPDhiaB?= NV3oUHJYUUN3ME2zMlY6KG6P MkHWNlI4OjN6N{G=
MIAPaCa-2 M2jobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[zWFAvODFvMUCwNEBvVQ>? M2jXZlQ5KGh? Ml7CTWM2OD1{OT6zOkBvVQ>? MYKyNlczOzh5MR?=
BxPC-3 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMlAyNTFyMECgcm0> NF3Me281QCCq MV7JR|UxRTNyLkK2JI5O NUXERZo3OjJ5MkO4O|E>
PANC-1 MVnGeY5kfGmxbjDBd5NigQ>? MWOwMVExODBibl2= MV6yOEBp NWrLNXpxcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v M3;oflIzPzJ|OEex
MIAPaCa-2 Ml;wSpVv[3Srb36gRZN{[Xl? M{D5VlAuOTByMDDuUS=> MWKyOEBp Mon1bY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;u MnLMNlI4OjN6N{G=
BxPC-3 M2jncWZ2dmO2aX;uJGF{e2G7 NIHmW28xNTFyMECgcm0> M4\FPVI1KGh? NVvkTI5rcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v MU[yNlczOzh5MR?=
RPMI-7951 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonIS2k2OD1|LkKgcm0> NVnje3FROjF5M{e1NFI>
SK-MEL-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPwS2k2OD12LkKgcm0> M2DzTFIyPzN5NUCy
A375 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfUS2k2OD14LkOgcm0> MYeyNVc{PzVyMh?=
SK-MEL-28 M{LKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPHTVUxRTdwNjDuUS=> NELu[ogzOTd|N{WwNi=>
SK-MEL-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPHTVUxRTFzIH7N MV:yNVc{PzVyMh?=
DB Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\m[Y01QMLiaB?= M{PWPGdKPTB;Mz61JI5O M{\6WlIyOjN5NUC4
Pfeiffer NIO0WJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nUSlQ5yqCq MWTHTVUxRTNwOTDuUS=> MorzNlEzOzd3MEi=
SU-DHL-5 NHrI[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrOc4k1QMLiaB?= MXrHTVUxRTBwMkOgcm0> M3;V[FIyOjN5NUC4
SU-DHL-8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\sOFjDqGh? NVuyZ3pFT0l3ME2xMlQhdk1? M{\SeVIyOjN5NUC4
WSU-DLCL-2 Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfyTHY1QMLiaB?= NUHKTpd{T0l3ME2xMlQhdk1? NUnrZmkxOjF{M{e1NFg>

... Click to View More Cell Line Experimental Data

In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

+ Expand
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Formulation: Dissolved and diluted in saline immediately before administration
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01100931 Completed NSCLC|Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 2010 Phase 1|Phase 2
NCT01038804 Completed Breast Cancer Astellas Pharma Inc December 2009 Phase 2
NCT01023386 Completed Cancer Astellas Pharma Inc November 2009 Phase 1
NCT01009775 Completed Melanoma Astellas Pharma Inc November 2009 Phase 2
NCT01007292 Completed Non-Hodgkins Lymphoma Astellas Pharma Inc November 2009 Phase 2
NCT00498914 Terminated Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell Refractory Astellas Pharma Inc June 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID